Sharni Marks, 31, was added to the waiting list in August 2022 without a specified surgery date. Despite being repeatedly informed she was a priority for the operation, it wasn't until March 2024 that ...

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

Hospital chaplains help patients and families, whether religious, atheist, agnostic, or "nothing in particular," find meaning ...

A groundbreaking, hour-long procedure using electrical currents to eliminate hard-to-reach prostate tumors is providing ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...

Even if a patient is unable to beat the disease, early-stage detection of cancer can play a crucial role in increasing their ...

Flossmoor resident and cancer survivor Ann Jackson launched the Center for Food Equity in Medicine at Flossmoor Community ...

Two recent studies from researchers at Washington University School of Medicine in St. Louis have identified a promising way ...

Sharni Marks agreed to have a double mastectomy after learning she had a high breast cancer risk but the operation came too ...

Updated results from the KATHERINE trial showed that adjuvant T-DM1 provided a significant improvement in overall survival and no evidence of long-term safety issues.

Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.

Questions about sex and intimacy often go unanswered for people with cancer. It's a glaring problem, especially for the ...